1. Home
  2. CION vs INBX Comparison

CION vs INBX Comparison

Compare CION & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CION

CION Investment Corporation

HOLD

Current Price

$9.55

Market Cap

527.0M

Sector

Finance

ML Signal

HOLD

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

HOLD

Current Price

$80.11

Market Cap

430.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CION
INBX
Founded
2011
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
527.0M
430.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CION
INBX
Price
$9.55
$80.11
Analyst Decision
Sell
Hold
Analyst Count
1
2
Target Price
$8.50
N/A
AVG Volume (30 Days)
413.5K
242.1K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
15.54%
N/A
EPS Growth
N/A
N/A
EPS
0.49
N/A
Revenue
$244,923,000.00
$1,400,000.00
Revenue This Year
N/A
$563.00
Revenue Next Year
N/A
N/A
P/E Ratio
$19.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.51
$10.81
52 Week High
$12.71
$94.57

Technical Indicators

Market Signals
Indicator
CION
INBX
Relative Strength Index (RSI) 41.17 49.85
Support Level $9.43 $76.22
Resistance Level $10.17 $94.57
Average True Range (ATR) 0.19 7.21
MACD -0.07 -1.31
Stochastic Oscillator 11.86 28.54

Price Performance

Historical Comparison
CION
INBX

About CION CION Investment Corporation

CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: